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Age-related macular degeneration is the leading cause of irreversible visual loss in elderly patients. After
photodynamic therapy, therapy targeting vascular endothelial growth factor (VEGF) therapy has become
the gold standard for treating neovascular age-related macular degeneration. Although monthly intra-
vitreal injections of anti-VEGF agents are the most promising treatment to improve and sustain vision,
as-needed treatments were administered based on the monthly examinations mainly because of cost-
effectiveness. However, as-needed treatments are considered reactive treatments that burden patients
and doctors with required monthly examinations and potentially decrease the improved vision. To
address this, the treat-and-extend regimen, a proactive treatment, has been advocated as individualized
medicine. This article reviews the characteristics of currently available anti-VEGF agents and treatment
strategies.
Copyright  2014, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Age-related macular degeneration (AMD) is the leading cause of
irreversible visual loss in elderly patients and the most common
cause of legal blindness in developed countries.1 In Asia, regional
studies have indicated that the prevalence rates of early AMD range
from 5.6% to 9.2% and those of advanced AMD range from 0.7% to
1.9% in elderly individuals.2e8 The prevalence of AMD in Asian
populations is increasing.2e8
Treatment options for AMD have improved dramatically over
the past 15 years. In April 2000, the US Food and Drug Adminis-
tration (FDA) approved the ﬁrst treatment for wet AMD: photo-
dynamic therapy (PDT) with intravenous administration of
verteporﬁn (Visudyne; Novartis International AG, Basel,
Switzerland). When PDT is applied, 689-nm laser irradiation acti-
vates verteporﬁn, a photosensitizer, in the eye and closes the
abnormal blood vessels. Although the Treatment of Age-Related
Macular Degeneration with Photodynamic Therapy (TAP) studycial relationships with any
mology and Visual Science,
iences, 1 Kawasumi, Mizuho-
ato).
e Ophthalmologic Society of Taiwgroup proved the effectiveness of PDT,9e17 its use slowly declined
after the more effective therapies targeting vascular endothelial
growth factor (VEGF) therapies were approved.
VEGF-A, generally referred to as VEGF, is the most important
member in the VEGF family and plays an important role in vascular
homeostasis, vascular permeability, and growth of new blood
vessels.18e20 The VEGF-A gene is organized into eight exons on
chromosome 6p21. Alternate gene splicing can generate nine iso-
forms, the most prevalent of which are VEGF121 and VEGF165. VEGF-
A is a dimeric glycoprotein that interacts with two tyrosine kinase
receptors, VEGFR-1 and VEGFR-2, located primarily on the endo-
thelial cells. Intravitreal injection of a VEGF-A inhibitor is currently
the primary treatment for neovascular AMD.
The ﬁrst FDA-approved anti-VEGF agent for neovascular AMD
was pegaptanib (Macugen, OSI Pharmaceuticals, Farmingdale,
NY, USA/Pﬁzer, New York, NY, USA). The FDA approved ranibi-
zumab (Lucentis; Genentech Inc., South San Francisco, CA, USA;
Novartis International AG) in June 2006. Bevacizumab (Avastin;
Genentech) was launched in 2004 for treating metastatic colon
cancer and has been used off-label to treat neovascular AMD.
More recently, aﬂibercept (Eylea; Regeneron, Tarrytown, NY,
USA; Bayer AG, Leverkusen, Germany) was approved in
November 2011.
This review summarizes the anti-VEGF treatment options and
current treatment strategies.an. Published by Elsevier Taiwan LLC. All rights reserved.
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2.1. Pegaptanib
Pegaptanib, a ribonucleic acid aptamer that inhibits only the
pathologic VEGF-A165 isoform, was the ﬁrst anti-VEGF agent to gain
approval for treating neovascular AMD. The VEGF Inhibition Study
in Ocular Neovascularization (VISION), that included two concur-
rent, prospective, randomized, double-masked, dose-ranging,
controlled Phase III clinical trials, showed that intravitreal pegap-
tanib administered at 6-week intervals for 48 weeks reduced the
risk of moderate and severe visual loss in patients with neovascular
AMD regardless of the angiographic subtype of choroidal neo-
vascularization (CNV).21e23 In the group treated with 0.3 mg of
pegaptanib, 70% of patients lost fewer than 15 letters of best-
corrected visual acuity (VA), compared with 55% in the control
group. The patients treated continuously with intravitreal pegap-
tanib during the 2nd year of the VISION study had less frequent
decreases in vision than those treated discontinuously with
pegaptanib or with PDT. Although intravitreal pegaptanib was
effective, it was replaced by monoclonal anti-VEGF antibodies.
2.2. Bevacizumab
Bevacizumab is a full-length, recombinant, humanized, mono-
clonal antibody with two VEGF-A binding sites.20 In 2004, the FDA
approved the drug because of its antiangiogenic effects for treating
metastatic colon cancer. Bevacizumab was designed originally to
have a long systemic half-life for use in cancer treatment, although
it has not been approved for intraocular use.24 Despite the lack of
clinical research to support its safety and efﬁcacy, anecdotal evi-
dence has led to its worldwide use because the drug has a target
speciﬁcity similar to that of ranibizumab and is less expensive.25e28
To address the safety and efﬁcacy concerns about bevacizumab
for treating neovascular AMD, the National Eye Institute commis-
sioned the Comparison of Age-Related Macular Degeneration
Treatment Trial (CATT). The 1-year results of the CATT study29 and
the Inhibition of VEGF Neovascularization (IVAN) study30 reported
the noninferiority of bevacizumab and the risk of cerebrovascular
events compared with ranibizumab.Table 1
The results of various treatment regimens for anti-VEGF therapies in the treatment of ne
MARINA ANCHOR prONTO HARBOR
Drug Ran Ran Ran Ran Ran
Treatment regimen Mon Mon 3 þ PRN Mon 3 þ PRN
No. injections at 12 mo 12 12 5.6 11.3 7.6
Mean letter improvement at 12 mo 7.2 11.3 9.3 10.1 8.2
Eyes losing fewer than 15 letters 95 96 95 98 95
Eyes gaining 15 letters or more 34 40 35 35 30
aOne line is equivalent to ﬁve letters.50
1þ PRN¼ pro re natawithout loading dose; 2q8¼ loading doseþ bimonthly; 3þ PRN¼ p
for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD; Bev
Antibody Ranibizumab in the Treatment of Neovascular AMD; Mon ¼ monthly;
Ran ¼ ranibizumab 0.5 mg; TAE ¼ treat-and-extend; VIEW ¼ .VEGF Trap-Eye, Investiga
Note. Column 2 (MARINA study) from “Ranibizumab for neovascular age-related macular
2006. Massachusetts Medical Society. Reproduced with permission. Column 3 (ANCHOR
degeneration,” by D.M. Brown et al, 2006, N Engl J Med, 355, p. 1432e44. Copyright 200
study) from “An optical coherence tomography-guided, variable dosing regimen with int
by A.E. Fung et al, 2007, Am J Ophthalmol, 143, p. 566e83. Copyright 2007. Elsevier B.V. Rep
safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related
Copyright 2013. American Academy of Ophthalmolog. Reproduced with permission. Colum
macular degeneration,” by D.F. Martin et al, 2011, Engl J Med, 364, p. 1897e908. Copy
(Toalster et al study) from “A 12-month prospective trial of inject and extend regimen fo
2013. Retina, 33, p. 1351e8. Copyright 2013. Lippincott Williams andWilkins. Reproduced w
(VEGF trap-eye) in wet age-related macular degeneration,” by J.S. Heier et al. 2012, Ophth2.3. Ranibizumab
The introduction of ranibizumab in 2006 was one of the most
exciting advances in the treatment of neovascular AMD. The drug is
an antibody fragment that binds to and inhibits all identiﬁed VEGF
isoforms and was designed speciﬁcally to treat wet AMD.18e20,31
Ranibizumab was engineered to have a 100-times higher binding
afﬁnity than bevacizumab, despite having one binding site. Given
the absence of the Fc segment, the antibody fragment was designed
to have a shorter systemic half-life, improved retinal penetration,
and a possible decreased Fc-related inﬂammatory reaction
compared to bevacizumab.32
The FDA approved ranibizumab after two large clinical trials
showed its effectiveness for treating neovascular AMD.31,33 The
Phase III Minimally Classic/Occult Trial of the Anti-VEGF Antibody
Ranibizumab in the Treatment of Neovascular AMD (MARINA) 31
evaluated the efﬁcacy and safety of ranibizumab for treating
minimally classic or occult with no classic CNV associated with
AMD. In this 2-year, prospective randomized, double-masked,
sham-controlled trial, the patients received monthly intravitreal
injections of ranibizumab. In Month 12, 94.5% of patients treated
with 0.3 mg of ranibizumab and 94.6% of patients treated with
0.5 mg ranibizumab lost fewer than 15 letters on the Early Treat-
ment of Diabetic Retinopathy Study (ETDRS) chart. The mean in-
creases in the ETDRS VA from baseline to Month 12 were 6.5 letters
in the 0.3-mg group and 7.2 letters in the 0.5-mg group (Table 1).
The Anti-VEGFAntibody for the Treatment of Predominantly Classic
Choroidal Neovascularization in AMD (ANCHOR)33 trial was also a
multicenter, randomized double-blind trial that compared the ef-
ﬁcacy and safety of ranibizumab and PDT with verteporﬁn in pa-
tients with predominantly classic CNV associated with neovascular
AMD. In Month 12, 94.3% of patients in the 0.3-mg group and 96.4%
in the 0.5-mg group lost fewer than 15 letters from baseline
compared with 64.3% in the verteporﬁn group. The mean increases
in the ETDRS VA from baseline to Month 12 were 8.5 letters in the
0.3-mg group and 11.3 letters in the 0.5-mg group; the verteporﬁn
group had a mean loss of 9.5 letters (Table 1). Both trials had low
rates of serious ocular or systemic adverse events.34,35
In these trials, ranibizumab was injected intravitreally on a
monthly basis (Fig. 1) over 2 years and resulted in a signiﬁcantovascular AMD.
CATT Toalster et al VIEW 1 VIEW 2
Ran Ran Bev Bev Ran Aﬂ Ran Aﬂ Ran
Mon 1 þ PRN Mon 3 þ PRN TAE 2q8 Mon 2q8 Mon
12 6.9 12 7.7 8 7 12 7 12
8.5 6.8 8 5.9 6.5a 7.9 8.1 8.9 9.4
94 95 94 92 95 95 94 96 96
34 25 31 28 26 31 31 31 34
ro re natawith loading dose; Aﬂ¼ aﬂibercept 2 mg; ANCHOR¼ Anti-VEGF Antibody
¼ bevacizumab 2 mg; MARINA ¼ Minimally Classic/Occult Trial of the Anti-VEGF
prONTO ¼ Prospective OCT Study with Ranibizumab for Neovascular AMD;
tion of Efﬁcacy and Safety in Wet AMD.
degeneration,” by Rosenfeld PJ et al. 2006, N Engl J Med, 355, p. 1419e31. Copyright
study) from “Ranibizumab versus verteporﬁn for neovascular age-related macular
6. Massachusetts Medical Society. Reproduced with permission. Column 4 (prONTO
ravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration,”
rinted with permission. Column 5 (HARBOR study) from “Twelve-month efﬁcacy and
macular degeneration,” by B.G. Busbee et al. 2013. Ophthalmology, 120, p. 1046e56.
n 6 (CATT study) from “Ranibizumab and bevacizumab for neovascular age-related
right 2011. Massachusetts Medical Society. Reproduced with permission. Column 7
r ranibizumab treatment of age-related macular degeneration,” by N. Toalster et al.
ith permission. Columns 8 and 9 (VIEW 1 and VIEW 2) from “Intravitreal aﬂibercept
almology 119, p. 2537e48. Copyright 2012. Elsevier B.V. Reproduced with permission.
Fig. 1. Treatment regimens for neovascular age-related macular degeneration using antivascular endothelial growth factor.
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burden of monthly injections, the interval between injections was
extended to lower costs and decrease the injection frequency. In
the Phase IIIb, multicenter, randomized, double-masked, sham
injection-controlled PIER36 and EXCITE37 studies, the efﬁcacy and
safety of ranibizumab were studied in patients with subfoveal CNV
with or without classic CNV secondary to AMD; patients were
treated monthly with intravitreal ranibizumab for the ﬁrst three
injections and every 3 months thereafter. The mean changes from
the baseline VA at 12 months were 16.3 letters, e1.6 letters,
and0.2 letters in the sham, 0.3-mg, and 0.5-mg groups in the PIER
study and the changes were 4.9 letters, 3.8 letters, and 8.3 letters in
the 0.3-mg quarterly, 0.5-mg quarterly, and 0.3-mgmonthly groups
in the EXCITE study, respectively. The outcomes were better than
the control group; however, the treatment effects were inferior to
those of the monthly regimen in the MARINA and ANCHOR studies.
Subsequently, the Prospective OCT Study with Ranibizumab for
Neovascular AMD (PrONTO) study, an open-label, prospective,
single-center, uncontrolled clinical study, in which optical coher-
ence tomography (OCT) was used, showed that a variable dosing
regimen could achieve visual outcomes as good as the original trials
with an average of 5.6 injections in the ﬁrst study year38 and 9.9
total injections over the 2-year study.39 Patients received three
consecutive monthly intravitreal injections of ranibizumab 0.5 mgFig. 2. The mean changes in the best corrected visual acuities and mean number of injectio
signiﬁcant difference in the best corrected visual acuities at any time points. (B) Signiﬁcan
loading dose regimen. M ¼ months. Note. From “Effect of a single-dose regimen of intravitre
S. Ikemori et al, 2012, J Clin Exp Ophthalmol 3, p. 221. Copyright 2012, S. Ikemori et al. Repriand were retreated based on the monthly examinations when any
of the retreatment criteria were met: a VA loss of more than ﬁve
letters, increased retinal thickness >100 mm seen on OCT, new
macular hemorrhages, a new area of classic choroidal neovascular
membranes, and persistent ﬂuid. Pro re nata (PRN) dosing was
administered (Fig.1). The study showed amean improvement in VA
of 9.3 letters in Month 12 and 11.1 letters in Month 24 (Table 1).39
The CATT Study Group29 conducted a large prospective trial that
compared a PRN regimen with monthly dosing and ranibizumab
with bevacizumab. In this multicenter, single-blind, noninferiority
trial, patients were randomized into one of four groups: ranibizu-
mab monthly, bevacizumab monthly, ranibizumab PRN, and bev-
acizumab PRN. In the PRN groups, injections were administered
only when active neovascularization persisted. The 1-year study
results showed that monthly bevacizumab was equivalent to
monthly ranibizumab, with means of 8.0 letters and 8.5 letters
gained, respectively. Bevacizumab PRN was equivalent to ranibi-
zumab PRN, with 5.9 letters and 6.8 letters gained, respectively
(Table 1). Ranibizumab PRN was equivalent to monthly ranibizu-
mab, although the comparison between bevacizumab PRN and
monthly bevacizumab was inconclusive. The mean number of in-
jections was 6.9 for ranibizumab PRN and 7.7 for bevacizumab PRN.
The IVAN study reported similar results in Great Britain30 in a
randomized head-to-head comparison of the efﬁcacy and safety ofns in single-dose and loading-dose regimens. (A) Neither regimen is associated with a
tly fewer injections are administered in the single-dose regimen compared with the
al ranibizumab in the treatment of neovascular age-related macular degeneration,” by
nted with permission.
Fig. 3. The relationship between the number of injections administered during the
ﬁrst 3 months and the frequencies of additional treatments administered in the 1 þ pro
re nata group. The fewer the number of injections that were administered during the
ﬁrst 3 months, the fewer additional treatments were administered during subsequent
months. M ¼ months. Note. From “Effect of a single-dose regimen of intravitreal
ranibizumab in the treatment of neovascular age-related macular degeneration,” by
S. Ikemori et al, 2012, J Clin Exp Ophthalmol 3, p. 221. Copyright 2012, S. Ikemori et al.
Reprinted with permission.
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evaluated to treat neovascular AMD. In that study, the comparison
at 1 year showed that the VA results were equivalent between the
bevacizumab and ranibizumab groups with monthly and PRN
injections.
Recently, in the HARBOR study40 evaluated the 12-month efﬁ-
cacy and safety of intravitreal ranibizumab 0.5 mg and 2.0 mgFig. 4. The treatment responses of a patient who was switched to the treat-and-extend reg
10e14 weeks. Therefore, the treat-and-extend regimen was adopted with the initial dosing
remained dry. Treatment was performed proactively and the dosing interval was extended
interval was shortened. Thereafter, the macula became dry again and the dosing interval w
intravitreal ranibizumab; IVR  2 ¼ two injections of intravitreal ranibizumab; IVR  3 ¼ th
E ¼ treat-and-extend.administered monthly and as needed in treatment-naïve patients
with subfoveal neovascular AMD. The results of this Phase III,
double-masked, multicenter, randomized, active treatment-
controlled study showed that at month 12, the ranibizumab
2.0-mg monthly group did not meet the prespeciﬁed superiority
comparison and the ranibizumab 0.5-mg and 2.0-mg PRN groups
did not meet the prespeciﬁed noninferiority comparison. All
treatment groups achieved clinically meaningful visual improve-
ments of þ8.2  10.1 letters. The PRN groups required about four
fewer injections (6.9 or 7.7) than the monthly groups (11.2e11.3;
Table 1).
In the CATT and IVAN studies, the PRN regimen started imme-
diately after the ﬁrst injection, but in the HARBOR study, the PRN
regimen started after three initial monthly (loading dosing) in-
jections (Fig. 1). In both groups, there were no signiﬁcant differ-
ences between the PRN and monthly groups. We previously
compared a loading regimen of ranibizumab with a single-dose
regimen for treating neovascular AMD41 and found that the
single-dose regimenwas associated with equivalent functional and
morphologic retinal improvement with fewer injections compared
with the loading regimen (Fig. 2), fewer injections during the ﬁrst 3
months, and less frequent additional treatments during subsequent
months (Fig. 3). These results suggested that the loading regimen
might not be essential to the starting treatment.
The PRN regimen required monthly visits to the ophthalmolo-
gist, fundus examinations, and OCT examinations, which also were
considerable burdens to patients, caregivers, the health care sys-
tem, and doctors. The need for continuous management with the
PRN regimen has the potential risk of delaying PRN (reactive)imen. With the pro re nata regimen, this patient had regular recurrences at intervals of
interval of 10 weeks. At the visit immediately prior to the next injection, the macula
to 14 weeks. However, because a recurrence was observed 14 weeks later, the dosing
as extended step by step. CRT ¼ central retinal thickness; IVR  1 ¼ one injection of
ree injections of intravitreal ranibizumab; M ¼ months; MV ¼ macular volume; T and
A. Kato et al. / Taiwan Journal of Ophthalmology 4 (2014) 3e8 7treatment and subsequent decreases in the once-improved vision.
To address these issues, Spaide42 recently advocated the treat-
(inject)-and-extend regimen, which is designed to minimize the
number of ofﬁce visits, ancillary testing, and intravitreal injections
and perform reactive rather than proactive treatment. Speciﬁcally,
patients received an injection at each visit independent of the
exudative changes. The interval between each visit (injection) was
extended by 2 weeks if the macula was dry or shortened if the
macula remained exudative (Fig. 1). Several retrospective studies
have reported the results with this regimen,43e46 and Fig. 4 shows
the effect of the treat-and-extend regimen in a case. Toalster et al47
conducted a recent (Table 1) prospective, multicenter, non-
randomized trial and found that the treat-and-extend protocol is
safe and efﬁcacious for treating neovascular AMD.
2.4. Aﬂibercept
A fourth anti-VEGF drug, aﬂibercept, was recently approved.
This is a fully human, recombinant fusion protein comprised of the
immunoglobulin (Ig) binding domain of VEGFR-1 and VEGFR-2
fused to the Fc portion of human IgG1. The drug works by bind-
ing tightly to three isoforms of growth factors (VEGF-A, VEGF-B,
and placental growth factor).48 Aﬂibercept has a long half-life in
the vitreous cavity, and is thus expected to be more effective and
long-standing, resulting in fewer injections. VIEW 1 and VIEW 2
(VEGF Trap-Eye, Investigation of Efﬁcacy and Safety in Wet AMD)49
were double-masked, multicenter, parallel-group, active-
controlled, randomized trials that compared monthly and every-2-
month administration of intravitreal aﬂibercept injections with
monthly ranibizumab injections. Patients with active subfoveal
CNV were randomized to intravitreal aﬂibercept 0.5 mg monthly
(0.5q4), 2 mg monthly (2q4), 2 mg every 2 months after 3 initial
monthly doses (2q8; Fig. 1), or ranibizumab 0.5 mg monthly. The
results showed that all aﬂibercept groups were noninferior and
clinically equivalent to monthly ranibizumab injections for the
primary endpoint. The 2q4, 0.5q4, and 2q8 regimens were effective
in 95.1%, 95.9%, and 95.1% of patients in the VIEW 1 study, and
effective in 95.6%, 96.3%, and 95.6% of patients in the VIEW 2 study,
respectively, whereas monthly ranibizumab was effective in 94.4%
of patients in both studies (Table 1). The ocular and systemic
adverse events were similar across the treatment groups. By
halving the number of monthly visits, the every-2-month regimen
of aﬂibercept may decrease the treatment burden. Less frequent
injections also may increase the ocular safety. Although the VIEW
studies were not powered to identify differences in rare but serious
intraocular and systemic complications, fewer injections may
substantially decrease the cumulative population risk of such
events.
3. Conclusion
The current evidence-based treatment strategy for managing
neovascular AMD supports the use of bevacizumab, ranibizumab,
or aﬂibercept. However, the optimal treatment regimen, especially
in the maintenance phase, remains controversial. For individual-
ized therapy, an adequate regimen should be chosen and, if
necessary, during long-term management, switched to a more
effective regimen such as monthly/every-2-month ﬁxed dosing
regimens, the PRN regimen, the treat-and-extend regimen, or
alternative strategies such as PDT.
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